Epidemiology and Treatment of Major Depressive Disorder

Major Depressive Disorder (MDD) is a leading cause of disability worldwide, characterised by persistent low mood, anhedonia, impaired concentration and functional decline. Epidemiological surveys indicate a lifetime prevalence of approximately 10–15%, with higher rates in women and in urban settings. Incidence rates vary by region but tend to peak in early adulthood, with a secondary rise in later life. Socioeconomic deprivation, chronic physical illness and exposure to adverse life events all elevate risk, while genetic heritability is estimated at 30–40%. MDD frequently coexists with anxiety, cardiovascular disease and metabolic disorders, amplifying overall burden and healthcare costs. Disability-adjusted life years attributable to MDD exceed those of many chronic conditions, owing largely to years lived with disability and elevated suicide risk. First-line treatments encompass pharmacotherapy—most commonly selective serotonin reuptake inhibitors (SSRIs) and serotonin–noradrenaline reuptake inhibitors (SNRIs)—and evidence-based psychotherapies such as cognitive behavioural therapy. Treatment selection is guided by severity, patient preference and comorbidity. A subset of patients shows resistance to standard interventions, prompting use of neuromodulation techniques (electroconvulsive therapy, repetitive transcranial magnetic stimulation) and rapid-acting agents such as ketamine. Emerging approaches integrate lifestyle modification, digital therapies and biomarker-guided stratification. Despite therapeutic advances, delays in diagnosis and under-treatment remain pervasive, underscoring the imperative for early identification, stepped care models and integrated physical and mental health services.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Epidemiology and Treatment of Major Depressive Disorder publication trend

The graph below shows the total number of articles in epidemiology and treatment of major depressive disorder across all publications each year (not limited to Nature Index journals).

Technical terms

Prevalence: The proportion of individuals in a population who have MDD at a specified time.

Incidence: The rate of new MDD cases occurring in a defined population over a given period.

Disability-Adjusted Life Years (DALYs): A metric combining years lived with disability and years of life lost due to premature mortality.

Selective Serotonin Reuptake Inhibitor (SSRI): A class of antidepressant medication that increases serotonin levels by inhibiting its reabsorption.

Neuromodulation: Therapeutic techniques that alter neuronal activity, such as electroconvulsive therapy and transcranial magnetic stimulation.

Comorbidity: The co-occurrence of MDD with other psychiatric or medical conditions, which can affect prognosis and treatment response.

References

1. Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010. PLOS Medicine (2013).
2. Cross-national epidemiology of DSM-IV major depressive episode. BMC Medicine (2011).
3. Lifestyle medicine for depression. BMC Psychiatry (2014).
4. Mental and somatic comorbidity of depression: a comprehensive cross-sectional analysis of 202 diagnosis groups using German nationwide ambulatory claims data. BMC Psychiatry (2020).
5. Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications. Neuroscience Bulletin (2021).
6. Epidemiology and costs of depressive disorder in Spain: the EPICO study. European Neuropsychopharmacology (2021).
7. Animal models for the study of depressive disorder. CNS Neuroscience & Therapeutics (2021).
8. Untreated duration predicted the severity of depression at the two-year follow-up point. PLOS ONE (2017).